163 related articles for article (PubMed ID: 24369118)
1. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
Das S; Edwards PA; Crockett JC; Rogers MJ
Biochim Biophys Acta; 2014 Apr; 1841(4):569-73. PubMed ID: 24369118
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
5. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
7. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
[TBL] [Abstract][Full Text] [Related]
9. A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton.
Ali N; Jurczyluk J; Shay G; Tnimov Z; Alexandrov K; Munoz MA; Skinner OP; Pavlos NJ; Rogers MJ
Small GTPases; 2015 Oct; 6(4):202-11. PubMed ID: 26399387
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
[TBL] [Abstract][Full Text] [Related]
11. Insights about the structure of farnesyl diphosphate synthase (FPPS) and the activity of bisphosphonates on the proliferation and ultrastructure of Leishmania and Giardia.
Gadelha APR; Brigagao CM; da Silva MB; Rodrigues ABM; Guimarães ACR; Paiva F; de Souza W; Henriques C
Parasit Vectors; 2020 Apr; 13(1):168. PubMed ID: 32248823
[TBL] [Abstract][Full Text] [Related]
12. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
13. The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates.
Ling Y; Li ZH; Miranda K; Oldfield E; Moreno SN
J Biol Chem; 2007 Oct; 282(42):30804-16. PubMed ID: 17724033
[TBL] [Abstract][Full Text] [Related]
14. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
15. A patent review of bisphosphonates in treating bone disease.
Holstein SA
Expert Opin Ther Pat; 2019 May; 29(5):315-325. PubMed ID: 31023104
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
17. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
19. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
20. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.
Liu J; Liu W; Ge H; Gao J; He Q; Su L; Xu J; Gu LQ; Huang ZS; Li D
Biochim Biophys Acta; 2014 Mar; 1840(3):1051-62. PubMed ID: 24246954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
